Best Hospitals for Myocardial Bridge Treatment in Chennai, India

A myocardial bridge occurs when a coronary artery segment — most frequently the mid-LAD (reported in 25–80% of autopsy series, symptomatic in 0.5–2.5% of angiographic populations) — courses intramurally through the ventricular myocardium for a distance ranging from a few millimetres to several centimetres. During systole, myocardial contraction compresses the tunnelled segment, generating a characteristic 'milking effect' on coronary angiography; diastolic flow, which normally accounts for the majority of coronary perfusion, is also impaired because residual post-systolic compression and elevated diastolic tone shorten the effective filling window. The haemodynamic consequence is a reduction in coronary flow reserve (CFR) — measurable by fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) during pharmacological provocation — leading to demand ischaemia, microvascular dysfunction, and, in severe cases, transient endothelial injury that paradoxically accelerates atherosclerosis proximal to the bridge.

• ELIGIBLE PATIENTS:
• Symptomatic patients (angina CCS Class II–IV, dyspnoea, palpitations, syncope) despite ≥3 months of optimised beta-blocker or non-dihydropyridine CCB therapy
• Objective haemodynamic significance confirmed by FFR ≤ 0.80 or diastolic FFR ≤ 0.76 under adenosine, or iFR ≤ 0.89
• Documented inducible ischaemia on non-invasive imaging: stress cardiac MRI, adenosine stress SPECT/PET-CT showing ≥10% ischaemic myocardium, or stress ECHO with wall-motion abnormalities in the LAD territory
• Bridge length ≥ 20 mm or depth ≥ 5 mm on IVUS/CTCA, predictive of surgical feasibility of unroofing myotomy
• +17 more

TIER 1 — OPTIMISED PHARMACOLOGICAL MANAGEMENT (First-Line): Beta-1 selective adrenergic blockade is the pharmacological cornerstone. Bisoprolol (2.5–10 mg/day) or metoprolol succinate (25–200 mg/day) reduce resting and peak-exercise heart rate, prolonging diastole and thereby increasing the effective coronary perfusion window. Target resting HR 55–65 bpm. For patients with beta-blocker intolerance or predominantly vasospastic phenotype, non-dihydropyridine CCBs — verapamil (240–480 mg/day SR) or diltiazem (120–360 mg/day SR) — are used. Ivabradine (5–7.5 mg BID) can be added as an adjunct for rate control without negative inotropy, particularly valuable in patients with borderline LV function. Antiplatelet therapy (aspirin 75–100 mg/day) is considered where proximal plaque is detected. Sublingual and long-acting nitrates are specifically contraindicated.

TIER 2 — SURGICAL UNROOFING MYOTOMY (Definitive Surgical Standard): Surgical unroofing (supracoronary myotomy) is the treatment of choice for symptomatic patients refractory to medical therapy, with bridge lengths amenable to dissection. The procedure involves cardiopulmonary bypass (CPB) with cardioplegic arrest; the myocardial fibres overlying the tunnelled coronary segment are sharply incised and excised, releasing the artery to an epicardial position. Operating time for the unroofing component is typically 15–45 minutes once CPB is established. Published case series (Iversen et al., Mohlenkamp, Alegria) report 88–95% freedom from angina at 2-year follow-up, normalisation of FFR post-procedure, and regression of stress-perfusion defects. Contemporary centres are now performing unroofing via minimally invasive right anterolateral mini-thoracotomy or robotic-assisted thoracoscopic approach (da Vinci Surgical System), reducing ICU stay to 24–48 hours and total hospital stay to 5–7 days versus 8–12 days for conventional sternotomy.

TIER 3 — CORONARY ARTERY BYPASS GRAFTING (CABG) — Selected Cases: CABG is preferred when: (a) significant proximal atherosclerosis co-exists and unroofing would not address the obstructive disease, (b) bridge anatomy precludes safe surgical unroofing (deep intramyocardial course, short segment with unfavourable angulation), or (c) prior unroofing has failed. Off-pump CABG (OPCAB) using the left internal mammary artery (LIMA) to the distal LAD — with or without sequential grafts — is favoured to avoid CPB-related morbidity. In patients with isolated bridge and no atherosclerosis, CABG provides competitive myocardial blood flow but creates a 'competitive flow' scenario that may reduce graft patency long-term; this is weighed carefully by the heart team. Total arterial revascularisation strategies using bilateral IMA or radial artery grafts are employed in younger patients.

TIER 4 — PERCUTANEOUS CORONARY INTERVENTION (PCI) — Exceptional and Discouraged: Percutaneous stenting of the bridged segment is generally contraindicated due to high stent fracture rates (reported 20–30% at 2 years), neo-atherosclerosis, ISR, and risk of perforation. Bare metal or drug-eluting stents placed within the bridge are associated with significant long-term failure. PCI is only considered in extreme high-surgical-risk cases as a bridge-to-decision strategy, with full patient counselling regarding inferior durability.

PHASE 1 — REMOTE PRE-CONSULTATION (Weeks 1–2, From Home Country):

• Patient submits medical records, coronary angiogram reports, CTCA images, and stress test results to GAF Healthcare's dedicated cardiology coordination team via secure portal
• GAF assigns a subspecialist interventional cardiologist or cardiothoracic surgeon for a telemedicine second opinion within 48–72 hours
• GAF provides a written treatment plan, itemised cost estimate, and destination recommendation (India or UAE) based on case complexity, urgency, and patient preference
• e-Medical visa application process initiated for India (typically approved in 3–5 business days); UAE visit/medical visa facilitated via sponsor letter

PHASE 2 — ARRIVAL AND DIAGNOSTIC WORK-UP (Days 1–4 In-Country):